Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 12;11:443–449. doi: 10.2147/IJWH.S204275

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Stochino Loi et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Pain symptom scores obtained for the VAS at baseline, after 10, 30, 60, 90 days and after 30 days from the end of the treatment with um-PEA followed by m(PEA/PLD) in patients affected from endometriosis. Intensity of chronic pelvic pain, dysmenorrhea, dyspareunia, and dyschezia showed a significant reduction at each time point compared to baseline. Thirty days after the end of the treatment, only chronic pelvic pain and dysmenorrhea mean score maintained a statistically significant difference compared to baseline. Data values are expressed as means±SD *A p-value of <0.05 was considered significant.